Sung Jong-Hyuk
Epi Biotech Co., Ltd., Incheon, South Korea; College of Pharmacy, Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea.
Biomed Pharmacother. 2023 Jan;157:113988. doi: 10.1016/j.biopha.2022.113988. Epub 2022 Nov 9.
We reviewed and summarized the latest reports on the characteristics of stem cells and follicular cells that are under development for hair loss treatment. Compared with conventional medicine, cell therapy could be effective in the long term with a single treatment while having mild adverse effects. Adipose-derived stem cells (ASCs) have the advantages of easy access and large isolation amount compared with dermal papilla cells (DPCs) and dermal sheath cup cells (DSCs), and promote hair growth through the paracrine effect. ASCs have a poor potential in hair neogenesis, therefore, methods to enhance trichogenecity of ASCs should be developed. DSCs can be isolated from the peribulbar dermal sheath cup, while having immune tolerance, and hair inductivity. Therefore, DSCs were first developed and finished the phase II clinical trial; however, the hair growth was not satisfactory. Considering that a single injection of DSCs is effective for at least 9 months in the clinical setting, they can be an alternative therapy for hair regeneration. Though DPCs are not yet studied in clinical trials, we should pay attention to DPCs, as hair loss is associated with gradual reduction of DPCs and DP cell numbers fluctuate over the hair cycle. DPCs could make new hair follicles with epidermal cells, and have an immunomodulatory function to enable allogeneic transplantation. In addition, we can expand large quantities of DPCs with hair inductivity using spheroid culture, hypoxia condition, and growth factor supplement. 'Off-the-shelf' DPC therapy could be effective and economical, and therefore promising for hair regeneration.
我们回顾并总结了有关正在研发用于治疗脱发的干细胞和毛囊细胞特性的最新报告。与传统药物相比,细胞疗法单次治疗即可长期有效,且副作用轻微。与毛乳头细胞(DPCs)和毛球鞘细胞(DSCs)相比,脂肪来源干细胞(ASCs)具有易于获取和分离量大的优点,并通过旁分泌作用促进头发生长。然而,ASCs在毛发新生方面潜力较差,因此应开发增强其毛囊诱导能力的方法。DSCs可从毛囊球周的毛球鞘中分离得到,具有免疫耐受性和毛发诱导能力。因此,DSCs率先开展并完成了II期临床试验;然而,其生发效果并不理想。鉴于在临床环境中单次注射DSCs至少9个月内有效,它们可作为毛发再生的替代疗法。尽管DPCs尚未进行临床试验研究,但我们应关注DPCs,因为脱发与DPCs数量逐渐减少有关,且DP细胞数量在毛发周期中会波动。DPCs可与表皮细胞形成新的毛囊,并具有免疫调节功能以实现同种异体移植。此外,我们可以通过球体培养、缺氧条件和生长因子补充来大量扩增具有毛发诱导能力的DPCs。“现货供应”的DPC疗法可能有效且经济,因此在毛发再生方面前景广阔。